Alphabet旗下Isomorphic Labs筹集21亿美元以扩大AI药物发现规模并推向临床试验
阅读原文· the-decoder.comIsomorphic Labs完成21亿美元B轮融资，由Thrive Capital领投。这家由DeepMind联合创始人Demis Hassabis领导的AI药物研究公司，将利用资金扩展内部平台IsoDDE，并加速候选药物向临床试验阶段推进。融资旨在提升AI驱动药物发现能力，推动多个项目进入临床测试，以缩短新药开发周期。
Alphabet's Isomorphic Labs raises $2.1 billion to scale AI drug discovery toward clinical trials
Isomorphic Labs, the AI drug research company led by Alphabet co-founder Demis Hassabis, has closed a $2.1 billion Series B funding round. Thrive Capital led the round, with participation from Alphabet, GV, MGX, Temasek, CapitalG, and the UK Sovereign AI Fund.
The funding will go toward expanding the company's in-house AI platform for drug development (IsoDDE), pushing its pipeline of drug candidates closer to clinical trials, and hiring globally. IsoDDE combines multiple proprietary AI models designed to work across different therapeutic areas and drug classes.